# US 9,518,089 B2 · Metallothionein-derived peptide fragments

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,518,089 B2
- Document ID: US9518089B2
- Status: Granted
- Kind: B2
- Application number: 14/086,233
- Filed: 2013-11-21
- Published: 2014-06-26
- Granted: 2016-12-13
- Earliest claimed: 2006-02-14
- Assignees: University of Tasmania
- Applicants: University of Tasmania
- Inventors: Vladimir Berezin; Elisabeth Bock; Milena Penkowa
- Web page: https://patentgrep.com/patent/US9518089B2

## CPC

- C07K 14/825: Metallothioneins
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/06: Antiarrhythmics
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/06: Antiasthmatics
- A61P 13/12: of the kidneys
- A61P 15/08: for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/06: Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A61P 19/10: for osteoporosis
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 21/04: for myasthenia gravis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/02: for peripheral neuropathies
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 25/32: Alcohol-abuse
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 31/12: Antivirals
- A61P 31/14: for RNA viruses
- A61P 31/20: for DNA viruses
- A61P 31/22: for herpes viruses
- A61P 33/06: Antimalarials
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 39/02: Antidotes
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to neural cell survival, differentiation and proliferation promoting peptide fragments derived from metallothioneins (MT), pharmaceutical compositions comprising said peptide fragments and uses thereof for treatment of diseases and conditions where the effects of stimulating neural cell proliferation, differentiation and/or survival, and/or stimulating neural plasticity associated with learning and memory are beneficial for treatment.

## Claims

### Claim 1

A peptide consisting of not more than 17 amino acids, wherein the peptide comprises the amino acid sequence SAGSCKCKESKSTS (SEQ ID NO:7) or a variant of SEQ ID NO:7, said variant having at least 90% sequence identity to SEQ ID NO:7, and wherein the peptide stimulates neurite outgrowth, neural cell survival, neural cell differentiation, and/or neural plasticity associated with learning and memory, and/or inhibits inflammation.

### Claim 2 (depends on 1)

The peptide according to claim 1, wherein said peptide consists of the amino acid sequence of SEQ ID NO:7.

### Claim 3 (depends on 1)

The peptide according to claim 1, wherein the length of the peptide is 15 amino acid residues.

### Claim 4 (depends on 1)

A pharmaceutical composition comprising a peptide according to claim 1.

### Claim 5

A compound comprising one or more peptides, wherein each of said one or more peptides consists of not more than 17 amino acids, wherein each of said one or more peptides comprises the amino acid sequence SAGSCKCKESKSTS (SEQ ID NO:7) or a variant of SEQ ID NO:7, said variant having at least 90% sequence identity to SEQ ID NO:7, and wherein each of said peptides stimulates neurite outgrowth, neural cell survival, neural cell differentiation, and/or neural plasticity associated with learning and memory, and/or inhibits inflammation.

### Claim 6 (depends on 5)

The compound according to claim 5, wherein said one or more peptides consist of a single peptide.

### Claim 7 (depends on 5)

The compound according to claim 5 comprising two or more of said peptide.

### Claim 8 (depends on 7)

The compound according to claim 7 comprising a dimer or a tetramer of said peptide.

### Claim 9 (depends on 7)

The compound according to claim 7 comprising a dendrimer of said peptide.

### Claim 10 (depends on 5)

A pharmaceutical composition comprising a compound according to claim 5.

### Claim 11

A pharmaceutical composition comprising a peptide consisting of not more than 20 amino acids, wherein the peptide comprises the amino acid sequence SAGSCKCKESKSTS (SEQ ID NO:7) or a variant of SEQ ID NO:7, said variant having at least 90% sequence identity to SEQ ID NO:7, and wherein the peptide stimulates neurite outgrowth, neural cell survival, neural cell differentiation, and/or neural plasticity associated with learning and memory, and/or inhibits inflammation.